This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.
Routine annual influenza vaccination is recommended for all patients 6 months of age and older who have no medical contraindications.
Bacterial superinfection at time of intubation occurred in <25 percent of patients; reduced antibiotic use seen with bronchoalveolar lavage-based management versus current guidelines
Risk factor assessment can identify candidates for screening; nonpharmacologic measures appropriate for all postmenopausal women
Routine annual vaccination is recommended for all patients 6 months of age and older who have no contraindications.
Poll was conducted before the FDA granted full approval to the Pfizer COVID-19 vaccine
To assess whether states and territories adhered to these FSMB recommendations, authors obtained copies of initial license medical applications from 50 US states, the District of Columbia, Guam, the Northern Mariana Islands, and the US Virgin Islands.
Screening for gestational diabetes at or after 24 weeks of gestation has moderate net benefit to improve maternal and fetal outcomes
Factors to consider include evaluation of secondary causes, optimization of diet and lifestyle interventions, implementation of statin therapy
eGFRcys resulted in smallest change in CKD prevalence among Black adults compared with race-blended, race-removed equations
